Major-Company-Funded Drilling at This Sub-$1 Copper-Gold Explorer Bonus
Content: Lilly Is Building the Largest API Drug Factory in U.S. History͏‌ ͏‌ ͏‌
͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌
͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌

Unsubscribe
<[link removed]>

September 8, 2026
View online ↗
<[link removed]>

A note from our friends at Resource Stock Digest(ad)
Copper is at record highs. Gold just blasted to $5K.

And while most juniors are forced to repeatedly raise money to keep the drills
turning...this sub – $1 copper-gold explorer has one of the world's largest
gold producers funding the work.
<[link removed]>

That's a huge advantage.

Meanwhile, shares still trade below $1.

And major-company-funded drilling is only the beginning.

Across two premier Australian mineral belts, drills are turning with plenty of
firepower for what comes next:

✔ Major-company-funded exploration Down Under
✔ An aggressive new multi-project drill campaign
✔ Multiple paths to copper-gold discovery
✔ A strong treasury and tight share structure
✔ BONUS: Our exclusive interview with the CEO

That's a lot of upside packed into a sub – $1 stock.

Click here to access our FREE online report...
<[link removed]>
and discover why this under-the-radar copper-gold explorer has all the
ingredients for a major breakout as the drills turn Down Under.



Bonus Article
Lilly Is Building the Largest API Drug Factory in U.S. History



Eli Lilly is not just expanding capacity. It is executing a manufacturing land
grab that may define the obesity drug market for the next decade, and the scale
of the bet is worth understanding clearly.

Why This Stock Now

Lilly has committed an additional $4.5 billion to expand two of its three
Lebanon, Indiana sites, pushing total Indiana capital expansion commitments
beyond $21 billion since 2020. That figure alone would be notable. But the more
important number is what the factory is for.

When the Lebanon API site opens in 2027, CEO David Ricks says it will be the
largest active pharmaceutical ingredient production site in U.S. history. The
previous record holder was also a Lilly facility. This is a company building
its own ceiling and then raising it.

The Business

Zepbound revenue increased to $4.1 billion in Q1 2026, up 79% from $2.3
billion in Q1 2025. Worldwide revenue in Q1 2026 hit $19.8 billion, a 56%
increase year over year driven by a 65% jump in volume. Those are the numbers
justifying the construction spend.

But tirzepatide is only half the production story now. On April 1, 2026, the
FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist
for adults with obesity (or overweight with at least one weight-related
comorbid condition), and Lilly says it can be taken any time of day without
food or water restrictions. Analysts have projected orforglipron could peak at
$30 to $40 billion in annual sales, and crucially, its small-molecule chemistry
is cheaper to manufacture and scale than peptide-based GLP-1 drugs.

What's Driving the Opportunity

The manufacturing build-out spans the country. Lilly says its U.S. capital
expansion commitments since 2020 total more than $50 billion, with projects in
places including Indiana, Texas, and Puerto Rico. In January 2026 alone, the
company committed more than $3.5 billion for a new facility in Fogelsville,
Pennsylvania. That site is expected to manufacture injectable medicines and
devices, including producing retatrutide, Lilly's next-generation triple-acting
GLP-1.

Analysts at Leerink have argued Lilly's scale could become a competitive
advantage as the market shifts toward a price-for-volume fight, enabling Lilly
to hold up even if prices eventually come down. That is the core thesis: build
enough factories that price compression does not break the model.

What Could Go Wrong

Orforglipron's approval marks a significant expansion of oral options, but at
least some clinicians have noted that oral GLP-1s may not match the weight-loss
efficacy of leading injectable GLP-1 agents in practice. A product that
underperforms on weight loss in head-to-head patient experience could cap
Foundayo's commercial ceiling well below the bull case.

The stock itself trades around $1,124 (as of September 8, 2026). That spread
reflects genuine uncertainty: Lilly can generate extraordinary revenue, but the
stock is pricing in a lot of that already.

The Bottom Line

Lilly's fiscal year 2026 guidance has been raised since the initial forecast:
as of the company's Q2 2026 update, it expects revenue of $84.0 to $86.0
billion, with non-GAAP EPS guidance of $35.50 to $37.00 per share. The
manufacturing investments are not a hedge against failure. They are how a
company that already generates those numbers intends to stay ahead of a market
it helped create. The factory in Indiana is the argument.



DISCLAIMER
This is a paid advertisement for informational and educational purposes only
and does not constitute financial advice. Investing involves risk and may not
be suitable for all individuals. Past performance does not guarantee future
results.
Trading Stocks Now is operated by Investing Media Solutions, LLC. We are not
licensed financial advisors. Always consult with a certified financial
professional before making investment decisions.

IMPORTANT NOTICE AND DISCLAIMER
Investing Media Solutions, LLC ("IMS"), the owner of this website (the
"Website"), cannot guarantee the accuracy or completeness of the information
contained in any article, email, newsletter, or other publication posted on or
viewed in connection with this website (the "Publications"). The author or
authors of those Publications are solely responsible for their contents. IMS
has not done any research or due diligence into the markets, industries, or
companies which may appear or be mentioned in the Publications.IMS will NOT be
liable for any loss or damage caused by a reader's reliance on information
posted on the Website or contained in the Publications.

FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE.
This Website and the Publications are for educational and informational
purposes only. This Website and the Publications do not purport to be a
complete analysis of any company's financial position. This Website, the
Publications or any statements made in the Publications are not, and should not
be construed to be, personalized investment advice directed to or appropriate
for any particular individual.This Website or the statements made in the
Publications should NOT be relied upon for purposes of transacting in any
securities posted on the Website or mentioned in the Publications, nor should
they be construed as a personalized recommendation to you to buy, sell, or hold
any position in any security posted on this Website or mentioned in any
Publications.b>

SUBSTANTIAL RISK IN INVESTMENT.
Any individual who chooses to invest in any securities including those
mentioned in the Publications should do so with caution.Investing or
transacting in securities involves substantial risk; you may lose some, all, or
possibly more than your original investment.Readers bear responsibility for
their own investment research and decisions and should review all investment
decisions with a licensed or registered investment professional.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER
Neither IMS nor any of its respective owners or employees are registered or
licensed as a securities broker-dealer, broker, an investment advisor, or an
investment advisor representative with the U.S. Securities and Exchange
Commission (SEC), any state securities regulatory authority, or any
self-regulatory organization.


For full policies, see our: Disclaimer
<[link removed]> | Privacy
<[link removed]> | Terms
<[link removed]>

Trading Stocks Now
203 N La Salle Street, Suite 2100 | Chicago, IL 60601

unsubscribe
<[link removed]>